Neuland Laboratories, a Hyderabad-based pharmaceutical company, has delivered massive returns in 13 years. In 2010, its share price was around ₹61.60. By February 27, 2025, it surged to nearly ₹11,000. A ₹1 lakh investment in 2010 is now worth ₹1.78 crore.
This growth comes from Neuland’s focus on active pharmaceutical ingredients (APIs) and expanding into new markets. The company’s commitment to quality and innovation has strengthened its position, boosting investor confidence and stock value.
Despite recent market dips, long-term investors have gained significantly. On February 27, 2025, the stock traded 6% lower at ₹10,915 on NSE. However, Neuland’s long-term trajectory remains strong.
Strategic investments in the pharmaceutical sector can yield high returns. Neuland’s success shows how focusing on core strengths and market expansion leads to financial growth. As the company innovates and expands, it remains a great example of long-term wealth creation.
